{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:17:10Z","timestamp":1788257830378,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Aspirin plus low-dose rivaroxaban reduces cardiovascular events in stable atherosclerosis; its effect on arterial inflammation in humans remains unclear. We tested whether adding low-dose rivaroxaban to aspirin reduces 18F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG PET\/CT)-detectable carotid plaque inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this single-centre, randomized, open-label, proof-of-concept trial with blinded endpoint assessment, adults with asymptomatic carotid stenosis (20\u201380%) and elevated carotid FDG uptake [target-to-background ratio (TBR) \u2265 1.6] were assigned 1:1 to aspirin (100 mg\/day) plus rivaroxaban (2.5 mg twice daily) or aspirin alone. The primary endpoint was per cent change in the most diseased segment (MDS) TBR of the index carotid artery at 12 months. Secondary endpoints included whole-vessel carotid TBR, aortic TBR, lipid and high-sensitivity C-reactive protein (hsCRP) changes. From September 2021 to December 2023, 92 patients were randomized (mean age 69.4 years; 88% men), and 81 (88%) completed paired imaging. Mean per cent changes in MDS TBR were \u22127.25% [95% confidence interval (CI), \u221211.03 to \u22123.48] with combination therapy and \u22127.36% (95% CI, \u221211.06 to \u22123.67) with aspirin alone (adjusted between-group difference, \u22121.50 percentage points, 95% CI, \u22126.20 to 3.21; P = 0.529). Secondary imaging endpoints were concordant. Laboratory parameters were similar, except for a nominal hsCRP difference without multiplicity adjustment. Minor bleeding occurred in four (8.7%) and one (2.2%) patients, respectively; no major bleeding or deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with carotid atherosclerosis, adding low-dose rivaroxaban to aspirin did not produce a detectable incremental reduction in 18F-FDG PET\/CT-assessed carotid plaque inflammation compared with aspirin alone over 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05797376<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjci\/jeag176","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:53:15Z","timestamp":1783597995000},"page":"1728-1740","source":"Crossref","is-referenced-by-count":0,"title":["Effect of low-dose rivaroxaban plus aspirin on 18F-FDG PET\/CT-detectable carotid plaque inflammation: a randomized trial"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7275-9302","authenticated-orcid":false,"given":"Tae Oh","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-0396","authenticated-orcid":false,"given":"Sangwon","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1082-0306","authenticated-orcid":false,"given":"Jeongryul","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1420-9484","authenticated-orcid":false,"given":"Jung Bok","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-0530","authenticated-orcid":false,"given":"Chong Hyun","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5779-5266","authenticated-orcid":false,"given":"Seong-Bong","family":"Wee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3719-4702","authenticated-orcid":false,"given":"Soo Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-4276","authenticated-orcid":false,"given":"Dae Hyuk","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-2159","authenticated-orcid":false,"given":"Cheol Whan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-1014","authenticated-orcid":false,"given":"Jun Gyo","family":"Gwon","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 5918 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-5952","authenticated-orcid":false,"given":"Seung-Whan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026090105474679200_jeag176-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa2415879","article-title":"Global effect of cardiovascular risk factors on lifetime estimates","volume":"393","author":"Magnussen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090105474679200_jeag176-B2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","volume":"86","author":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/01.CIR.89.1.36","article-title":"Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology","volume":"89","author":"van der Wal","year":"1994","journal-title":"Circulation"},{"key":"2026090105474679200_jeag176-B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"2026090105474679200_jeag176-B5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2026090105474679200_jeag176-B6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090105474679200_jeag176-B7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090105474679200_jeag176-B8","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N Engl J Med"},{"key":"2026090105474679200_jeag176-B9","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1161\/01.CIR.0000020548.60110.76","article-title":"Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography","volume":"105","author":"Rudd","year":"2002","journal-title":"Circulation"},{"key":"2026090105474679200_jeag176-B10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jacc.2007.05.024","article-title":"(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials","volume":"50","author":"Rudd","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcmg.2016.04.007","article-title":"Thresholds for arterial wall inflammation quantified by (18)F-FDG PET imaging: implications for vascular interventional studies","volume":"9","author":"van der Valk","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090105474679200_jeag176-B12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026090105474679200_jeag176-B14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jacc.2006.03.069","article-title":"Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography","volume":"48","author":"Tahara","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/RLU.0000000000004146","article-title":"Fully automatic quantitative measurement of 18F-FDG PET\/CT in thymic epithelial tumors using a convolutional neural network","volume":"47","author":"Han","year":"2022","journal-title":"Clin Nucl Med"},{"key":"2026090105474679200_jeag176-B16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00259-013-2569-6","article-title":"Optimizing 18F-FDG PET\/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels","volume":"41","author":"Bucerius","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090105474679200_jeag176-B17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2967\/jnumed.114.142596","article-title":"Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement","volume":"56","author":"Huet","year":"2015","journal-title":"J Nucl Med"},{"key":"2026090105474679200_jeag176-B18","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026090105474679200_jeag176-B19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards)","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"},{"key":"2026090105474679200_jeag176-B20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2026090105474679200_jeag176-B21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.118.033544","article-title":"Protease-activated receptor-2 plays a critical role in vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice","volume":"138","author":"Hara","year":"2018","journal-title":"Circulation"},{"key":"2026090105474679200_jeag176-B22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a direct oral factor Xa inhibitor, attenuates atherosclerosis by alleviating factor Xa-PAR2-mediated autophagy suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2026090105474679200_jeag176-B23","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0735-1097(01)01289-X","article-title":"Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay","volume":"37","author":"Feldman","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jacc.2018.12.075","article-title":"Vascular inflammation in subclinical atherosclerosis detected by hybrid PET\/MRI","volume":"73","author":"Fern\u00e1ndez-Friera","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B25","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.jacc.2019.04.046","article-title":"Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients","volume":"73","author":"Darmon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026090105474679200_jeag176-B26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2026090105474679200_jeag176-B27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090105474679200_jeag176-B28","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jeag176\/68763713\/jeag176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/9\/1728\/68763713\/jeag176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/9\/1728\/68763713\/jeag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:33Z","timestamp":1788256113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/27\/9\/1728\/8733195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,13]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeag176","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,13]]}}}